(BDX)

This portfolio focuses on generating a growing stream of dividend income by investing in companies that consistently increase dividends. I reinvest dividends into more shares of the companies I alread...

Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.

Medical device maker Becton Dickinson has begun discussions to sell its life sciences division, valued at $21 billion, and is in talks with competitors such as Thermo Fisher Scientific and Danaher , t...

Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Br...

Becton Dickinson gets rating buy in my first coverage of this stock. Macro demand for medtech and surgical supplies could favor this globally diversified firm with an active portfolio and growth pipel...

BD's recall of Alaris infusion pumps following software issues has been classified as the most severe recall by the FDA. A suspension of sales may hurt the top line going forward.

BD advances its clinical trial for the bioabsorbable GalaFLEX LITE scaffold, aiming to improve outcomes in breast implant revision surgeries and patient recovery.

The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings i...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.